This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F13%3A10124202%21RIV14-MZ0-11150___/
n11http://localhost/temp/predkladatel/
n12http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n21http://linked.opendata.cz/resource/domain/vavai/subjekt/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n20http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F13%3A10124202%21RIV14-MZ0-11150___
rdf:type
skos:Concept n18:Vysledek
rdfs:seeAlso
http://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2012.04643.x/pdf
dcterms:description
Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for chronic plaque psoriasis. However, its use is hampered by the risk of liver fibrosis. The study compared the results of serial measurements of serum fibrosis markers during the remission-induction phase of treatment with MTX to those of patients on biologic therapy and long-term MTX therapy (> 2 years). Serum concentrations of hyaluronic acid (HA), N-terminal propeptide of collagen type III (PIIINP) and the results of two multi-test algorithms Fibrotest and Hepascore were evaluated in patients with chronic plaque psoriasis (N=24, age: 28-79 years, baseline psoriasis area and severity index PASI 13.5, range 2.2-33) at baseline and weeks 16 and 26 after the start of pharmacokinetically-guided therapy with MTX (Group A). Patients on established therapy with biologics (N=15, Group B) and long-term MTX users (N=10, Group C) with the mean baseline PASI scores of 0.9 and 1.2 were studied in parallel cohorts. At baseline, HA, Hepascore and PIIINP were correlated with PASI of Group A patients. At weeks 16 and 26, HA decreased by 48 % and 40 % (P<0.001) and Hepascore by 31 (P<0.01) and 20% (P<0.05), respectively. PASI75 (GREATER-THAN OR EQUAL TO75% improvement from baseline PASI) was observed in 76% of Group A patients by week 26 and the absolute decreases in PASI and both fibrosis markers were correlated (HA: r=0.49, P=0.018, Hepascore: r=0.47, P=0.022). In contrast, no significant within-group differences were found in HA and Hepascore results of patients in the groups B and C. PIIINP and Fibrotest were stable in all groups. It is concluded that the fibrosis markers hyaluronic acid and Hepascore (the multiple test algorithm which includes hyaluronic acid) are less liver specific and more prone to reflect psoriasis activity than PIIINP and Fibrotest. Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for chronic plaque psoriasis. However, its use is hampered by the risk of liver fibrosis. The study compared the results of serial measurements of serum fibrosis markers during the remission-induction phase of treatment with MTX to those of patients on biologic therapy and long-term MTX therapy (> 2 years). Serum concentrations of hyaluronic acid (HA), N-terminal propeptide of collagen type III (PIIINP) and the results of two multi-test algorithms Fibrotest and Hepascore were evaluated in patients with chronic plaque psoriasis (N=24, age: 28-79 years, baseline psoriasis area and severity index PASI 13.5, range 2.2-33) at baseline and weeks 16 and 26 after the start of pharmacokinetically-guided therapy with MTX (Group A). Patients on established therapy with biologics (N=15, Group B) and long-term MTX users (N=10, Group C) with the mean baseline PASI scores of 0.9 and 1.2 were studied in parallel cohorts. At baseline, HA, Hepascore and PIIINP were correlated with PASI of Group A patients. At weeks 16 and 26, HA decreased by 48 % and 40 % (P<0.001) and Hepascore by 31 (P<0.01) and 20% (P<0.05), respectively. PASI75 (GREATER-THAN OR EQUAL TO75% improvement from baseline PASI) was observed in 76% of Group A patients by week 26 and the absolute decreases in PASI and both fibrosis markers were correlated (HA: r=0.49, P=0.018, Hepascore: r=0.47, P=0.022). In contrast, no significant within-group differences were found in HA and Hepascore results of patients in the groups B and C. PIIINP and Fibrotest were stable in all groups. It is concluded that the fibrosis markers hyaluronic acid and Hepascore (the multiple test algorithm which includes hyaluronic acid) are less liver specific and more prone to reflect psoriasis activity than PIIINP and Fibrotest.
dcterms:title
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers
skos:prefLabel
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers
skos:notation
RIV/00216208:11150/13:10124202!RIV14-MZ0-11150___
n18:predkladatel
n21:orjk%3A11150
n3:aktivita
n15:P
n3:aktivity
P(NS10364)
n3:cisloPeriodika
8
n3:dodaniDat
n5:2014
n3:domaciTvurceVysledku
n9:1802054 n9:2975858
n3:druhVysledku
n17:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
62273
n3:idVysledku
RIV/00216208:11150/13:10124202
n3:jazykVysledku
n19:eng
n3:klicovaSlova
biomarker; fibrosis; methotrexate; psoriasis
n3:klicoveSlovo
n4:biomarker n4:fibrosis n4:psoriasis n4:methotrexate
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[14634A29BE33]
n3:nazevZdroje
Journal of the European Academy of Dermatology and Venereology
n3:obor
n10:FR
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
6
n3:projekt
n12:NS10364
n3:rokUplatneniVysledku
n5:2013
n3:svazekPeriodika
27
n3:tvurceVysledku
Hroch, Miloš Hůlek, Petr Vaněčková, Jaroslava Vávrová, Jaroslava Šimková, Marie Chládek, Jaroslav
n3:wos
000321893600011
s:issn
0926-9959
s:numberOfPages
8
n20:doi
10.1111/j.1468-3083.2012.04643.x
n11:organizacniJednotka
11150